Arovella Therapeutics Ltd (ALA) — Cash Flow-to-Debt Ratio
Arovella Therapeutics Ltd (ALA) has a Cash Flow-to-Debt Ratio of -1.28x as of December 2025, meaning its operating cash flow of AU$-1.71 Million could theoretically repay -1% of its total liabilities (AU$1.33 Million) in one year. Explore Arovella Therapeutics Ltd (ALA) cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arovella Therapeutics Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Arovella Therapeutics Ltd across 13 annual periods. Also explore ALA total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Arovella Therapeutics Ltd (2013–2025)
Year-by-year debt coverage analysis for Arovella Therapeutics Ltd. For market capitalisation and broader financial context, see Arovella Therapeutics Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.55x | AU$-6.93 Million | AU$1.52 Million | ▼ -35.2% |
| 2024 | -3.36x | AU$-6.91 Million | AU$2.06 Million | ▲ +11.2% |
| 2023 | -3.78x | AU$-6.40 Million | AU$1.69 Million | ▲ +3.7% |
| 2022 | -3.93x | AU$-6.27 Million | AU$1.60 Million | ▼ -89.1% |
| 2021 | -2.08x | AU$-3.54 Million | AU$1.71 Million | ▼ -85.4% |
| 2020 | -1.12x | AU$-2.88 Million | AU$2.57 Million | ▼ -2.2% |
| 2019 | -1.10x | AU$-2.50 Million | AU$2.28 Million | ▼ -122.8% |
| 2018 | -0.49x | AU$-2.55 Million | AU$5.18 Million | ▼ -82.2% |
| 2017 | -0.27x | AU$-854.22K | AU$3.16 Million | ▲ +56.4% |
| 2016 | -0.62x | AU$-1.80 Million | AU$2.91 Million | ▲ +30.9% |
| 2015 | -0.90x | AU$-3.15 Million | AU$3.52 Million | ▼ -49.3% |
| 2014 | -0.60x | AU$-2.61 Million | AU$4.36 Million | ▼ -50.7% |
| 2013 | -0.40x | AU$-1.61 Million | AU$4.04 Million | — |